- 17 June
-
From May 20 to 22, the first Eurasian International Medical Forum was held in Ekaterinburg. The event was dedicated to the 80th anniversary of Victory in the Great Patriotic War. The Forum brought together over 1,000 participants and 250 experts from Russia, India, China and Belarus. Medsintez Plant took an active part in scientific program of the Forum and demonstrated its latest developments in the field of import-substituting drugs.
- 13 June
-
The X (XXXI) National Diabetes Congress with international participation was held in Moscow from May 27 to 30, 2025. The event was dedicated to the topic «Diabetes mellitus – a non-infectious pandemic of the 21st century. Macro- and microvascular complications. Issues of interdisciplinary interaction». The Congress was dedicated to the 100th anniversary of the Russian Association of Endocrinologists, the Endocrinology Service of the Russian Federation and the Research Center for Endocrinology.
- 10 June
-
In May 2025, pharmaceutical plant Medsintez Plant LLC joined the leading enterprises that were awarded the status of National Champion based on the results of a comprehensive expert selection. Getting the status of National Champion is a significant event for Medsintez Plant, which emphasizes its contribution to the development of the pharmaceutical industry and strengthening the drug safety of Russia.
- 25 April
-
From April 15 to 18, Ekaterinburg hosted the 6th international specialized exhibition and forum Healthcare of the Urals–2025. This year, 130 companies from 34 cities of Russia and the Republic of Belarus took part in the event, presenting over 1000 units of medical equipment and goods. The residents of the Ural Biomedical Cluster were traditionally among the participants, as well as its collective member – the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region.
- Home
- Cluster members
- Ural Biomedical Company LLC
Ural Biomedical Company LLC
Genetic and gene and cell technologies (GCT), which make it possible to modify the properties of cells in a targeted manner, is a direction that the UN has officially recognized as a technology of the 21st century.
Hopes for the treatment of the most severe and massive diseases, such as cardiovascular, oncological and metabolic diseases, are associated with success in the development of GCT.
The small innovative enterprise Ural Biomedical Company LLC acts as a coordinator in this area, bringing together the efforts of specialists from the Department of Molecular and Cellular Technologies of the Ural State Medical University and the Laboratory of Cell and Gene Therapy Technology of the Institute of Medical Cellular Technologies in conducting an R&D cycle and implementing innovative projects for the development, production and use of a new generation of personalized medicines based on gene and gene-cell technologies based on the patented developments of one of the leading scientific schools in Russia – Professor O. G. Makeev's School.
Currently, the studies coordinated by Ural Biomedical Company LLC are at different stages of preclinical and clinical trials, which are highly recognized both in Russia and abroad – in particular, representatives of the above scientific school have obtained dozens of patents, have been awarded gold medals at European and Russian forums and exhibitions of biomedical technologies.
According to the National Society of Regenerative Medicine, a unique product for the Russian and world markets – AversGel – a gel for natural skin rejuvenation based on components of a certified human stem cell line, entered the top 10 breakthrough technologies in Russia in 2017 with the comment: "These technologies will remain with us for a long time. They will change the economy and politics, make a breakthrough in medicine, leave a cultural mark. Some of them are just taking shape, while others can take more than a decade to develop. But you need to know about them right now.”
